29 July - Monday

Preliminary program - subject to change.

07:45 - 08:45

New Investigator Session

Chair: Bhagwat Prasad, University of Washington, Seattle, Washington, USA

All investigators within their first ten years of receiving their highest earned degree are welcome to attend and participate in this session. Continental breakfast will be available to attendees. Additional details will be posted once available.

09:00 - 10:00

How Technology, Big Data and Systems Approaches Are Transforming 21st Century Healthcare

Leroy Hood, Providence St. Joseph Health, Renton, Washington, USA

10:00 - 11:00

ISSX Membership Meeting

ISSX President, Tom Baillie, University of Washington, Seattle, Washington, USA

ISSX Members are invited to attend this special member session to learn about Society updates and initiatives.

13:00 - 15:00

Concurrent Sessions: Symposia 1 and 2

Symposium 1: Personalized Medicine: Use of Pharmacogenomics and Other Patient-specific Factors to Individualize Drug Dosing and Treatment
Co-Chairs: Ann Daly, Newcastle University, Newcastle upon Tyne, United Kingdom and Tsuyoshi Fukuda, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

Warfarin: A Paradigm for Individualized Dosing
Munir Pirmohamed, University of Liverpool, Liverpool, United Kingdom

Relevance of Transporter and Metabolic SNPs to Pediatric Treatment
Tsuyoshi Fukuda, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

CPIC Guidelines and Implementation to Date
Kelly Caudle, St Jude Children’s Research Hospital, Memphis, Tennessee, USA

Personalised Treatment of Cancer
Howard McLeod, Moffitt Cancer Center, Tampa, Florida, USA


Symposium 2: State of the Art for Organs on Chips

Co-Chairs: Edward Kelly, University of Washington, Seattle, Washington, USA and Roos Masereeuw, Utrecht University, Utrecht, the Netherlands

Kidney Organoids for Disease Modeling and High Throughput Screening
Benjamin Freedman, University of Washington, Seattle, Washington, USA

Lecture Title to be Confirmed
Paul Vulto, Mimetas, Lieden, Netherlands

Lecture Title to be Confirmed
Danilo Tagle, NCATS, NIH, Bethesda, Maryland, USA

Biofabrication of Liver Constructs for Drug Toxicity Studies
Kerstin Schneeberger, Utrecht University, Utrecht, Netherlands

15:30 - 17:30

Concurrent Sessions: Symposia 3 and 4

Symposium 3: Quantitative Pharmacokinetic and Pharmacology Methods and Strategies in the Discovery and Development of Biotherapeutics
Co-Chairs: Hannah Jones, Pfizer Inc., Cambridge, Massachusetts, USA and Joe Balthasar, University of Buffalo, Buffalo, New York, USA

Development and Application of a PBPK Model for Large Molecules in Pfizer
Hannah Jones, Pfizer Inc., Cambridge, Massachusetts, USA

PBPK and PKPD Modeling to Investigate Engineered Antibodies
Tatsuhiko Tachibana, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan

PBPK Models for Predicting Human PK for Monoclonal Antibodies and Other Large Molecule Modalities
Iain Gardner, Certara UK Limited (Simcyp Division), Sheffield, United Kingdom

Systems PK/PD Model Informed Discovery and Development of Cancer Immunotherapy
Dhaval Shah, University of Buffalo, Buffalo, New York, USA

Symposium 4: Microbiome-environment-drug Interactions: Emerging Tools and Applications
Co-Chairs: Julia Yue Cui, University of Washington, Seattle, Washington, USA and Sumio Ohtsuki, Kumamoto University, Kumamoto, Japan

Impact of Intestinal Flora on Host Metabolism of Drug, Sugar, and Lipid Metabolism
Sumio Ohtsuki, Kumamoto University, Kumamoto, Japan

Activity-based Profiling of the Microbiome Response to Chemical Exposures
Aaron Wright, Pacific Northwest National Laboratory, Richland, Washington, USA

Impact of the Human Gut Microbiome on Drug Disposition
Peter Turnbaugh, NCATS, University of California San Francisco, San Francisco, California, USA

Lecture Title to be Confirmed
Julia Yue Cui, University of Washington, Seattle, Washington, USA

17:30 - 19:30

Poster Viewing in Exhibit Hall